On October 21, 2022 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, reported a research agreement with a Top 10 Global Healthcare company ("Healthcare Company") (based on 2021 revenues) (Press release, NeuBase Therapeutics, OCT 21, 2022, View Source [SID1234622271]). For this research, the Healthcare Company will evaluate NeuBase’s PATrOL technology for three monogenic genetic diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NeuBase’s PATrOL platform is a PNA-based technology designed to address disease at the root of causality to help patients with rare and common diseases by editing, upregulating, or downregulating gene function. PATrOL gene editing is differentiated in that it does not require bacterial enzymes (e.g., CRISPR-Cas9), which potentially increases fidelity and reduces immunogenicity to provide a safer solution to patients for in vivo gene editing.

"Our PATrOL technology enables us to create a series of peptide nucleic acids (PNAs) designed to target a genetic mutation and recruit the cell’s own high fidelity nucleic acid repair machinery to resolve the mutation," stated Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase. "We look forward to working with our Healthcare Company partner to explore our novel gene editing technology for several genetic diseases."

Under the terms of the agreement, NeuBase and the Healthcare Company will collaborate on the evaluation of drug candidates for three undisclosed indications. The Healthcare Company will have the exclusive opportunity, subject to certain terms and conditions, to license and develop the drug candidates created under this research evaluation agreement.

On October 21, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that it will release its third quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, November 3, 2022 (Press release, Autolus, OCT 21, 2022, View Source [SID1234622270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

On October 21, 2022 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26th, 2022 in New York, NY (Press release, Lantern Pharma, OCT 21, 2022, View Source [SID1234622269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panna Sharma, Lantern’s CEO & President, will be hosting an A.I. and Drug Development Panel at 10:00 a.m. ET focused on how A.I. is transforming the cost, pace, and risks involved in developing a new drug.

Panelists will include noted experts from Weill Cornell, Volastra Therapeutics, InveniAI, and Hepion Pharmaceuticals.
Lantern Pharma is scheduled to present at the conference on Wednesday, October 26th at 1:00 p.m. ET.
Webcast Link: View Source
Registration Link: View Source
Lantern Pharma management will be available for one-on-one meetings to be held throughout the conference.

On October 21, 2022 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported an update of its financial guidance for 2022, after preliminary completion of the latest evaluation of its third quarter and nine months 2022 financial performance (Press release, MorphoSys, OCT 21, 2022, View Source [SID1234622263]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys updates its financial guidance based on the preliminary unaudited consolidated results for the first nine months 2022. Preliminary Monjuvi (tafasitamab-cxix) U.S. Net Product Sales are US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 and US$ 64.1 million (€ 60.2 million) for the first nine months of 2022. For the full year of 2022, MorphoSys now expects Monjuvi U.S. Net Product Sales to be approximately US$ 90 million (previously: US$ 90 to US$ 110 million). The previous financial guidance for 2022 was provided by MorphoSys on July 26, 2022 and reiterated on August 3, 2022 and can be found at www.morphosys.com. All other aspects of the financial guidance for 2022 remain unchanged.

On October 21, 2022 QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) reported its plans to release results for the third quarter of 2022 (Press release, Qiagen, OCT 21, 2022, View Source [SID1234622262]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!